12 min listen
Ruben A. Mesa, MD, FACP - Risk-Adapted Treatment Algorithms in Myelofibrosis: Optimizing Patient Outcomes With JAK Inhibitors
Ruben A. Mesa, MD, FACP - Risk-Adapted Treatment Algorithms in Myelofibrosis: Optimizing Patient Outcomes With JAK Inhibitors
ratings:
Length:
14 minutes
Released:
Feb 15, 2023
Format:
Podcast episode
Description
Please visit answersincme.com/AJK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloproliferative neoplasms reviews strategies for optimizing outcomes for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Recognize treatment goals in the management of patients with myelofibrosis; Outline strategies to assess patient risk, including risk stratification of patients with myelofibrosis; and Review the latest clinical implications of Janus kinase (JAK) inhibitors in the treatment of myelofibrosis.
Released:
Feb 15, 2023
Format:
Podcast episode
Titles in the series (84)
Antonio González Martin, MD, PhD - Exploring the Evolving Role of PD-1/PD-L1 Inhibitors in Cervical Cancer: Setting Sights on Locally Advanced Disease: Please visit answersincme.com/BZG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology